Physician
Gastroenterology
Dr. Marc G. Ghany, MD
|
|
Give Review
Marc G. Ghany, MD is an expert in the field of Gastroenterology. Marc Ghany is a published doctor and has 101 publications published. The lastest was: '10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.'
Publications
- An Epidemiologic Investigation of a Case of Acute Hepatitis E.
- Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.
- Building bridges and providing transparency to the hepatitis C virus drug approval process.
- Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and HBV Genotype.
- QUEST for a cure for hepatitis C virus: the end is in sight.
- Long-term therapy of chronic delta hepatitis with peginterferon alfa.
- The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
- The Hepatitis B Vaccine Protects Re-Exposed Healthcare Workers, but Does Not Provide Sterilizing Immunity.
- Current and future therapies for hepatitis C virus infection.
- Acute hepatitis C: to treat or not to treat.
- Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy.
- What the Infectious Disease Physician Needs to Know About Pegylated Interferon and Ribavirin.
- Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.
- Discordance Among Transient Elastography, Aminotransferase to Platelet Ratio Index, and Histologic Assessments of Liver Fibrosis in Patients with Chronic Hepatitis C.
- Re: HEP-11-1628 - An update on treatment of genotype 1 chronic hepatitis c virus infection: 2011 practice guidelines by the american association for the study of liver...
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.
- Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C.
- S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders.
- Management of untreated and nonresponder patients with chronic hepatitis C.
- Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment.
- Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C.
- Hepatitis B virology for clinicians.
- Ribavirin improves early responses to peginterferon through improved interferon signaling.
- Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner.
- Antiviral resistance and hepatitis B therapy.
- Evolution of therapy for chronic hepatitis B: progressing from the simple to the complex.
- Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy.
- Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
- Efforts to define the natural history of chronic hepatitis C continue.
- Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement.
- Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection.
- Assessment and management of chronic hepatitis B.
- Assessment of liver fibrosis: palpate, poke or pulse?
- Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort.
- Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
- Management of chronic hepatitis B.
- E1 therapeutic vaccination for chronic hepatitis C: all that glitters is not gold.
- Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin.
- Progression of fibrosis in chronic hepatitis C.
- Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.
- Laser capture microdissection of single cells from complex tissues.
- Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment.
- Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers.
- Expression of chemokine and inhibitory receptors on natural killer cells: effect of immune activation and HIV viremia.
- A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
- Pushing the treatment envelope for chronic hepatitis C--is more necessarily better?
- Cellular immune responses to the hepatitis B virus polymerase.
- Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.
- Pilot study of interferon gamma for chronic hepatitis C.
- Hepatitis B e Antigen--the dangerous endgame of hepatitis B.
- Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells.
- Association between body mass index and diabetes and hepatocellular carcinoma.
- Two cases of thyroid storm-associated cholestatic jaundice.
- The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis.
- Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.
- Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C.
- Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.
- A rapid immunochromatographic assay for hepatitis B virus screening.
- 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.
- Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B.
- Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.
- Correlation between serum HCV RNA and aminotransferase levels in patients with chronic HCV infection.
- Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs.
- A young woman with cirrhosis: autoimmune hepatitis vs. alpha 1-antitrypsin deficiency.
- Long-term therapy of chronic hepatitis B with lamivudine.
- Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.
- Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial.
- Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.
- Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection.
- HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
- Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.
- The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis.
- Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
- Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.
- Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
- Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus.
- Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.
- Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.
- Diagnosis, management, and treatment of hepatitis C: an update.
- Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
- Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
- Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.
- Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepati...
- DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial.
- Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.
- Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial.
- Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepa...
- Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.
- Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.
- Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma.
- Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial.
- Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.
- Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
- Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C.
- Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
- Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
- Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial.
- Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
- A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.
- Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.
Doctors Specialties
- Gastroenterology
- Transplant Hepatology
Accepted Insurances
Education
-
Tulane University -
Yale-New Haven Hospital -
Royal College of Surgeons Ireland
Helpful Reviews
Similar Doctors
|
|
Leonard B. Seeff |
|
|
Dr. Yaron Rotman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jay H. Hoofnagle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tim F. Greten, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jeffrey S. Abrams, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Donald A. O'Kieffe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick E. Young, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen A. Wank, MD |
|
|
Dr. Steven P. Armbruster, MD |
|
|
Dr. Gary M. Roggin, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael J. Schwartz, MD |
|
Dr. Louis Y. Korman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ajay Bakhshi, MD
This Doctor is OpenDoctor Recommended.
|